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Fusion procedures have become a necessary element of the surgeon’s armamentarium in the treatment of lumbar degenerative disease. The application of 
these surgical procedures continues to expand as techno-
logical advances facilitate our ability to achieve a solid 
arthrodesis and our understanding of the pathological and 
biomechanical aspects of degenerative spine disease im-
proves.
Utilizing national Medicare data from the Dartmouth 
Atlas Project, Weinstein et al. have identified a steady in-
crease in lumbar fusion surgeries between 1992 and 2003 
in patients over the age of 65, from 0.3/1000 to 1.1/1000 
enrollees.6 A 20-fold variation in regional rates among en-
rollees was also identified, representing the largest regional 
variation for any surgical procedure. During this interval 
the annual amount spent for lumbar fusion surgeries rose 
500%, to 482 million dollars in 2003.6 Although Deyo et 
al. identified a slight decline in the number of lumbar fu-
sion procedures performed among Medicare beneficiaries 
between 2002 and 2007, the number of complex fusion 
procedures increased 15-fold, from 1.3 to 19.9 procedures 
for every 100,000 beneficiaries.1 With this increase in the 
complexity of surgery performed, an increase in costs, 
morbidity, and resource utilization has also been observed. 
Utilizing the Nationwide Inpatient Sample database, Ka-
lanithi et al. demonstrated a 70% increase in the rate of 
complications following lumbar fusion in patients over 
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Fusion procedures are an accepted and successful management strategy to alleviate pain and/or neurological 
symptoms associated with degenerative disease of the lumbar spine. In 2005, the first version of the “Guidelines for 
the performance of fusion procedures for degenerative disease of the lumbar spine” was published in the Journal of 
Neurosurgery: Spine. In an effort to incorporate evidence obtained since the original publication of these guidelines, 
an expert panel of neurosurgical and orthopedic spine specialists was convened in 2009. Topics reviewed were essen-
tially identical to the original publication. Selected manuscripts from the first iteration of these guidelines as well as 
relevant publications between 2005 through 2011 were reviewed. Several modifications to the methodology of guide-
line development were adopted for the current update. In contrast to the 2005 guidelines, a 5-tiered level of evidence 
strategy was employed, primarily allowing a distinction between lower levels of evidence. The qualitative descriptors 
(standards/guidelines/options) used in the 2005 recommendations were abandoned and replaced with grades to reflect 
the strength of medical evidence supporting the recommendation. Recommendations that conflicted with the original 
publication, if present, were highlighted at the beginning of each chapter. As with the original guideline publication, 
the intent of this update is to provide a foundation from which an appropriate treatment strategy can be formulated.
(http://thejns.org/doi/abs/10.3171/2014.4.SPINE14257)
Key WorDs      •      lumbar spine      •      lumbar fusion       •       practice guidelines
Abbreviation used in this paper: NASS = North American Spine 
Society.
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65 years of age when compared with patients between 45 
and 64 years of age.4 As a result of this increasing rate of 
lumbar fusions, expansion of indications, and complexity 
of surgery, the socioeconomic impact has become more 
closely scrutinized, requiring that medical evidence jus-
tify the application of these procedures.
In 2005, the first iteration of the “Guidelines for the 
performance of fusion procedures for degenerative dis-
ease of the lumbar spine” was published in the Journal 
of Neurosurgery: Spine.5 This comprehensive compen-
dium outlined 16 topics pertaining to the performance 
of lumbar fusion surgery for degenerative spinal disease, 
providing 50 recommendations based on a review of the 
medical literature published between 1966 and 2003. 
Given the time dependency of a literature review, clinical 
practice guidelines are evolving documents that require 
periodic updating as new information and knowledge ac-
cumulates. The purpose of the current series, “Guideline 
update for the performance of fusion procedures for de-
generative disease of the lumbar spine,” is to incorporate 
the more recent medical evidence that has been published 
since the original publication and establish new recom-
mendations.
In 2009, an expert panel of neurosurgical and ortho-
pedic spine surgeons was convened, many having partici-
pated in the original guidelines effort. All members had 
experience with clinical guideline development and had 
completed the evidence-based medicine course devel-
oped by the North American Spine Society (NASS). As 
the current document is to serve as an update, identical 
topics and search terms were selected from the original 
guideline publication.
Methodology
The development of evidence-based clinical guide-
lines is a multistep process, the basis of which has been 
well described.3 The current update was constructed 
through a series of steps, similar to the previous guide-
line efforts:
1. Selection of topics to study
 a. As this is an update, the same topics from the  
  original guidelines were chosen.
2. Performing a literature search
 a. Searches were limited to English studies  
  investigating human subjects.
3. Collecting relevant studies for review
  a. Searches were reviewed and studies specifically  
  investigating the topic under consideration were  
  chosen.
4. Assessing the quality and strength of the evidence
  a. Modified NASS strategy
5. Formulation of recommendations based on the  
 evidence
    a. Modified NASS strategy
6. Panel review of the evidentiary tables
 a. Consensus method used to establish uniformity of 
  response
7. Submission of guidelines for peer review
As previously stated, the first two steps were based 
on the topics and search terms used in the original guide-
line submission.
The literature searches were conducted with the as-
sistance of a librarian who had extensive experience 
formulating and conducting evidence-based literature 
searches. Search terms from the original guidelines were 
used and altered as deemed necessary. Searches of the Na-
tional Library of Medicine and Cochrane database were 
conducted from the termination of the original searches, 
in 2003, through December of 2011. The abstracts were 
reviewed and all relevant publications were selected for 
formal assessment. Bibliographies were reviewed from 
selected publications and appropriate studies selected. 
The specifics of each search, including the MeSH terms, 
are described in each chapter.
Topics were assigned to individual panel members, 
with the primary assignee intended to perform the assess-
ment of evidence and a second panel member intended to 
review the evidentiary table prior to presentation to the 
entire panel. Each assignee formulated preliminary rec-
ommendations based on their review of the literature. The 
expert panel completed final determination of the levels 
of evidence and recommendation grades after reviewing 
the evidentiary tables.
In an effort to conform to spine guidelines published 
from other clinical societies, as well as maintain an objec-
tive assessment of the evidence, the current panel elected 
to deviate from the methodology employed in the original 
guidelines and use the NASS strategy for evidence as-
sessment and recommendation grading (see Tables 1 and 
2). As there are no uniformly accepted methods for down-
grading evidence, the panel decided to limit downgrading 
of evidence by no more than one level to avoid excessive 
subjectivity.
As the current publication is intended to serve as an 
update of the previous guidelines, the decision was made 
to include all Level I and II evidence from the original 
guidelines. A reevaluation of these studies utilizing the 
NASS strategy was necessary. The panel agreed not to 
include lower levels of evidence, as these studies were not 
likely to enhance the updated recommendations.
Quality of Medical Evidence
The foundation for any evidence-based practice 
guidelines rests on the assessment of medical evidence. 
The NASS assessment of medical evidence is a 5-tiered 
strategy that assigns separate levels to “case series” and 
“expert opinion” (see Table 1). This highlights the major 
difference between the 3-tiered approach used in the orig-
inal guideline publication, where the decision was made 
to combine all lower levels of evidence. This distinction 
becomes relevant when grading recommendations.
Each study was categorized according to the underly-
ing objective—therapeutic, diagnostic, or prognostic. The 
initial level of evidence was determined by defining the 
overall study design. For example, a randomized control 
trial would start as Level I evidence while a retrospective 
review could start no higher than Level III. The study’s 
methodology was then analyzed to determine if the nec-
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essary criteria were fulfilled to maintain the initial lev-
el of evidence. These criteria were in part based on the 
NASS strategy as well as the panel’s scientific and clini-
cal experience and are listed in Table 3. Downgrading of 
therapeutic studies occurred if at least 1 major or 2 minor 
limitations were identified. For the other study categories, 
these criteria were considered as well as those specifi-
cally outlined in Table 3.
Studies that met all criteria and contained data that 
would significantly alter current medical practice would 
be upgraded; however, no study met these criteria. Dur-
ing the panel review of the evidentiary tables, consensus 
method was used to resolve any disagreement.2 Ultimate-
ly, the panel achieved unanimous agreement for every 
study evaluated in the evidentiary tables.
Formulation of Treatment Recommendations
The primary investigator for a given topic, prior to the 
consensus development process, formulated preliminary 
recommendations. During panel discussions the decision 
was made as to which studies would serve as the basis for 
the final recommendations, and these studies were includ-
ed within the “Scientific Foundation” for a given topic. In 
general, if high-quality evidence (Level I and II data) was 
available to formulate a recommendation, lesser-quality 
evidence was not included. Studies of low quality that con-
flicted with high-quality evidence were not included in the 
evidentiary tables, but this discrepancy was mentioned in 
the “Scientific Foundation.”
The expert panel assigned a grade to each recom-
TABLE 1: Levels of medical evidence for primary research topic
Level
Therapeutic Study— 
Investigating the Effectiveness  
of Treatment
Diagnostic Study— 
Investigating the Accuracy of  
a Diagnostic Test
Prognostic Study— 
Investigating the Impact That  
a Baseline Characteristic Has  
on Disease Outcome
Economic Analysis— 
Formulating an Economic 
Model to Determine the Cost 
Effectiveness of Treatment
I 1. Well-designed RCT w/  
 appropriate statistical analysis/ 
 reporting
  a. No major limitations*
  b. No more than 1 minor  
   limitation*
2. Systematic review of well- 
 designed RCTs w/ consistent  
  findings
1. Evaluation of previously  
 established diagnostic test/ 
 criteria
  a. Consecutively enrolled  
   patients
  b. Application of reference  
   “gold” standard
2. Systematic review of Level I  
 studies
1. Well-designed prospective  
 study w/ patient enrollment  
 occurring at same time point in 
 disease process
  a. At least 80% follow-up at  
   study end point
2. Systematic review of Level I  
 studies
1. Inclusion of sensible/realistic  
 costs & treatment alternatives
  a. Data derived from  
   multitude of sources
  b. Multi-way sensitivity  
   analysis performed
2. Systematic review of Level I  
 studies
II 1. Prospective comparative study 
2. Systematic review of Level  
 II studies or review of Level I  
  studies w/ inconsistent findings
1. Formulation of diagnostic  
 criteria/test
  a. Consecutively enrolled  
   patients
  b. Application of reference  
   “gold” standard
2. Systematic review of Level II  
 studies
1. Retrospective review
2. Study population derived from  
 untreated controls of an RCT
3. Inferior prospective study
  a. Patient enrolled at  
   different time points
  b. Less than 80% follow-up
4. Systematic review of Level II  
 studies
1. Inclusion of sensible/realistic  
 costs & treatment alternatives
  a. Data derived from limited  
   studies
  b. Multi-way sensitivity  
   analysis performed
2. Systematic review of Level II  
 studies
III 1. Case control studies
2. Retrospective comparative  
 studies
3. Systematic review of Level III  
 studies
1. Study of nonconsecutive  
 patients
  a. Failure to consistently  
   apply reference “gold”  
   standard
1. Case control study 1. Study analysis based on  
 incomplete costs & failure to  
 consider alternative treatments
2. Systematic review of Level III  
 studies
IV 1. Case series 1. Case control study
2. Utilization of poor reference  
 standard
1. Case series 1. Failure to include sensitivity  
 analysis
V 1. Expert opinion 1. Expert opinion 1. Expert opinion 1. Expert opinion
* See Table 3 for listing of major and minor limitations of study design utilized to determine level of medical evidence. RCT = randomized controlled trial.
TABLE 2: Recommendation grades
Grade Definition
A Good evidence—2 or more Level I studies w/ consistent  
  findings
B Fair evidence—single Level I study or multiple Level II or  
  III studies w/ consistent findings
C Poor evidence—single Level II study or multiple Level IV  
 or V studies
I Insufficient evidence for recommendation—single Level  
 III, IV, or V study; studies of equivalent strength w/  
  conflicting findings/conclusions
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mendation based on the strength of the supporting evi-
dence. Instead of a qualitative description of recommen-
dation grade, as performed in the original guidelines, the 
expert panel chose to use recommendation grades modi-
fied from NASS (see Table 2). The baseline NASS strat-
egy was used, but modifications were included to address 
instances in which a single study provided evidence for 
a specific recommendation. The highest-quality recom-
mendation, Grade “A,” required 2 or more Level I stud-
ies with consistent findings. Fair evidence, either a single 
Level I study or consistent findings from multiple Level 
II or III studies, was given a Grade “B” recommenda-
tion. Poor-quality evidence would support a Grade “C” 
recommendation, including either a single Level II study 
or consistent findings from Level IV or V studies. Rec-
ommendations based on a single Level III or lower-level 
study or studies of equal strength that demonstrated con-
flicting results were given a Grade “I” designation.
Summary
As greater emphasis is placed on validating the sur-
gical treatments for our patients, particularly with regard 
to spine surgery, the necessity for evidence-based clini-
cal guidelines is becoming increasing apparent. Given 
the time dependency of a literature review, all clinical 
practice guidelines are evolving documents that require 
periodic updating. As an update, the current publica-
tion was intended to build on the foundation established 
by the original lumbar fusion guidelines. After careful 
evaluation, the current expert panel felt it necessary to re-
consider the methodology of previous guidelines. These 
changes were incorporated in an effort to perform a more 
objective evaluation and allow for easier communication 
among clinicians from other subspecialty organizations.
Although emphasis has recently been placed on evi-
dence-based clinical practice and improving the method 
of scientific investigation, the panel frequently encoun-
tered studies of inferior quality. Despite this limitation, 
one objective of the current update is to identify areas 
of future research and stimulate more objective clinical 
investigation. It is the hope that the well-informed reader 
will carefully evaluate the “Scientific Foundation” to un-
derstand the justification for a given recommendation. As 
with previous guideline efforts, there is a risk of specialty 
bias as no nonsurgical stakeholders were involved in the 
development of this update. Although the potential for 
this bias exists, considerable effort was taken to try and 
objectively evaluate the current literature.
These guidelines are not intended to provide rigid 
treatment algorithms. Instead, it is hoped that this update 
will serve as a comprehensive review of the current state 
of the literature and provide the reader with a founda-
tion to formulate an appropriate individualized treatment 
plan for a given patient. Furthermore it is the intent of any 
guideline to identify current limitations of the literature 
and stimulate further investigational research.
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